Mulligan LM - Search Results

1

Comprehensive immunohistochemical analysis of RET, BCAR1, and BCAR3 expression in patients with Luminal A and B breast cancer subtypes.

Pavanelli AC, Mangone FR, Yoganathan P, Bessa SA, Nonogaki S, de Toledo Osório CAB, de Andrade VP, Soares IC, de Mello ES, Mulligan LM, Nagai MA. Pavanelli AC, et al. Among authors: mulligan lm. Breast Cancer Res Treat. 2022 Feb;192(1):43-52. doi: 10.1007/s10549-021-06452-9. Epub 2022 Jan 15. Breast Cancer Res Treat. 2022. PMID: 35031902

2

Five distinct deleted regions on chromosome 17 defining different subsets of human primary breast tumors.

Nagai MA, Medeiros AC, Brentani MM, Brentani RR, Marques LA, Mazoyer S, Mulligan LM. Nagai MA, et al. Among authors: mulligan lm. Oncology. 1995 Nov-Dec;52(6):448-53. doi: 10.1159/000227509. Oncology. 1995. PMID: 7478429

3

Allelic loss on distal chromosome 17p is associated with poor prognosis in a group of Brazilian breast cancer patients.

Nagai MA, Pacheco MM, Brentani MM, Marques LA, Brentani RR, Ponder BA, Mulligan LM. Nagai MA, et al. Among authors: mulligan lm. Br J Cancer. 1994 Apr;69(4):754-8. doi: 10.1038/bjc.1994.142. Br J Cancer. 1994. PMID: 7908218 Free PMC article.

4

Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.

Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA, Gardner E, Scheumann GF, Jackson CE, Tunnacliffe A, et al. Eng C, et al. Among authors: mulligan lm. Hum Mol Genet. 1994 Feb;3(2):237-41. doi: 10.1093/hmg/3.2.237. Hum Mol Genet. 1994. PMID: 7911697

5

Analysis of PTEN and the 10q23 region in primary prostate carcinomas.

Feilotter HE, Nagai MA, Boag AH, Eng C, Mulligan LM. Feilotter HE, et al. Among authors: mulligan lm. Oncogene. 1998 Apr 2;16(13):1743-8. doi: 10.1038/sj.onc.1200205. Oncogene. 1998. PMID: 9582022

6

The RET receptor is linked to stress response pathways.

Myers SM, Mulligan LM. Myers SM, et al. Among authors: mulligan lm. Cancer Res. 2004 Jul 1;64(13):4453-63. doi: 10.1158/0008-5472.CAN-03-3605. Cancer Res. 2004. PMID: 15231654

7

From genes to decisions: evolving views of genotype-based management in MEN 2.

Mulligan LM. Mulligan LM. Cancer Treat Res. 2004;122:417-28. Cancer Treat Res. 2004. PMID: 16209059 Review.

8

Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B.

Gujral TS, Singh VK, Jia Z, Mulligan LM. Gujral TS, et al. Among authors: mulligan lm. Cancer Res. 2006 Nov 15;66(22):10741-9. doi: 10.1158/0008-5472.CAN-06-3329. Cancer Res. 2006. PMID: 17108110

9

A novel RET kinase-beta-catenin signaling pathway contributes to tumorigenesis in thyroid carcinoma.

Gujral TS, van Veelen W, Richardson DS, Myers SM, Meens JA, Acton DS, Duñach M, Elliott BE, Höppener JW, Mulligan LM. Gujral TS, et al. Among authors: mulligan lm. Cancer Res. 2008 Mar 1;68(5):1338-46. doi: 10.1158/0008-5472.CAN-07-6052. Cancer Res. 2008. PMID: 18316596

10

RET-mediated gene expression pattern is affected by isoform but not oncogenic mutation.

Hickey JG, Myers SM, Tian X, Zhu SJ, V Shaw JL, Andrew SD, Richardson DS, Brettschneider J, Mulligan LM. Hickey JG, et al. Among authors: mulligan lm. Genes Chromosomes Cancer. 2009 May;48(5):429-40. doi: 10.1002/gcc.20653. Genes Chromosomes Cancer. 2009. PMID: 19226610

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

137 results

Search Page